Anti-MERS-CoV S2 Protein Antibody (G4)

Catalog No.

RVV07505

Species reactivity

Middle East respiratory syndrome-related coronavirus (isolate UnitedKingdom/H123990006/2012) (MERS-CoV) (Betacoronavirus England 1)

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S2, S, S2 Protein

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

K9N5Q8

Applications

ELISA, FCM, IF, Neutralization, SPR

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

G4

Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608

Newcastle Disease Virus Displaying an Ectodomain of Middle East Respiratory Syndrome Coronavirus Spike Protein Elicited Robust Humoral and Cellular Immunity in Mice., PMID:39852781

Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673

Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach., PMID:39148710

The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2., PMID:39093891

Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans., PMID:39058596

Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination., PMID:38725111

Low-sugar universal mRNA vaccine against coronavirus variants with deletion of glycosites in the S2 or stem of SARS-CoV-2 spike messenger RNA (mRNA)., PMID:38011546

Repurposing Navitoclax to block SARS-CoV-2 fusion and entry by targeting heptapeptide repeat sequence 1 in S2 protein., PMID:37804480

An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen., PMID:37534910

Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses., PMID:36942851

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease., PMID:36889306

Bioinformatic analysis of the S protein of human respiratory coronavirus., PMID:36657625

Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses., PMID:36618428

Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice., PMID:36444622

A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein., PMID:36075899

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody., PMID:35862475

Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome., PMID:35853863

Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability., PMID:35841885

Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants., PMID:35476528

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain., PMID:35417303

Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause severe disease., PMID:35291291

Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021., PMID:35113873

Cross-reactive antibodies after SARS-CoV-2 infection and vaccination., PMID:34812143

Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination., PMID:34737318

Stabilized coronavirus spike stem elicits a broadly protective antibody., PMID:34710354

Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray., PMID:34704808

Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray., PMID:33824382

Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates., PMID:33741598

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies., PMID:33731724

The Potential of Developing Pan-Coronaviral Antibodies to Spike Peptides in Convalescent COVID-19 Patients., PMID:33677719

Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2., PMID:33486372

Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals., PMID:33199863

Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates., PMID:32995773

Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein., PMID:32967955

Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike., PMID:32913581

Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2., PMID:32700671

Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray., PMID:32511324

A novel luciferase immunosorbent assay performs better than a commercial enzyme-linked immunosorbent assay to detect MERS-CoV specific IgG in humans and animals., PMID:32501446

Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein., PMID:31945421

Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection., PMID:31801868

Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice., PMID:31589656

Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning., PMID:31544848

Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein., PMID:31526954

Middle East Respiratory Syndrome Coronavirus in Dromedaries in Ethiopia Is Antigenically Different From the Middle East Isolate EMC., PMID:31275264

Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD., PMID:30621343

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape., PMID:29514901

Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections., PMID:29093093

MERS-CoV spike protein: a key target for antivirals., PMID:27936982

Evaluation of candidate vaccine approaches for MERS-CoV., PMID:26218507

Document Download

Anti-MERS-CoV S2 Protein Antibody (G4).pdf